GENE ONLINE|News &
Opinion
Blog

Clostridium Difficile Infection
Nestle and Seres Land First-Ever Fecal Microbiota Product Approval From FDA
2023-04-27
BARDA Exercises $23.8 Million to Support Phase 3 Trial of Vedanta’s Encouraging Microbiome Therapy
2021-10-07
R&D
BARDA Funds Development of Live Biotherapeutic Product Against C. difficile Infections
2020-10-05
Seres Therapeutics’ Microbiome Therapy for Recurrent C. difficile Infections, Shines in Phase 3
2020-08-12
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top